Crown Capital Partners
Crown Capital Partners, established in 2000, is a Toronto-based specialty finance company with an office in Calgary. It specializes in providing alternative debt financing to middle-market companies, both private and public, in Canada and the United States. The firm offers tailored financing solutions, including subordinated term and bridge loans, perpetual debt, income streaming, and royalties, with minimal or no ownership dilution. These solutions enable business owners to retain majority economic rewards while providing Crown with stable, predictable cash flows. Crown's investee firms are diverse by sector and geography, and are typically successful enterprises with experienced leadership teams and positive cash flow.
Medicure Inc. is a specialty pharmaceutical company based in Winnipeg, Canada, that focuses on the research, development, and commercialization of cardiovascular therapies primarily for the U.S. hospital market. Established in 1997, Medicure initially dedicated its efforts to research and development but shifted to a commercial focus in 2008. The company markets AGGRASTAT, an injection used to treat acute coronary syndrome, and offers other products including ZYPITAMAG for lipid disorders and ReDS, a non-invasive device for measuring lung fluid in congestive heart failure management. Medicure also provides Sodium Nitroprusside injection for blood pressure regulation and surgical procedures. The company is committed to enhancing patient outcomes while pursuing growth through product development and acquisition opportunities, solidified by the FDA approval of AGGRASTAT's new label in 2013, which has facilitated sales growth and profitability. Medicure’s operational subsidiaries include Medicure International, based in Barbados, which holds U.S. rights to AGGRASTAT, and Medicure USA, involved in product distribution in the U.S.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.